Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study

Trial Profile

Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2013

At a glance

  • Drugs Lansoprazole (Primary) ; Rabeprazole (Primary)
  • Indications Reflux oesophagitis
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Janssen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top